EyePoint Pharmaceuticals (FRA:PV3B) Total Assets : €302.91 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is EyePoint Pharmaceuticals Total Assets?

EyePoint Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was €302.91 Mil.

During the past 12 months, EyePoint Pharmaceuticals's average Total Assets Growth Rate was -6.90% per year. During the past 3 years, the average Total Assets Growth Rate was -19.80% per year. During the past 5 years, the average Total Assets Growth Rate was -6.90% per year. During the past 10 years, the average Total Assets Growth Rate was 34.10% per year.

During the past 13 years, EyePoint Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 243.60%. The lowest was -43.00%. And the median was -14.00%.

Total Assets is connected with ROA %. EyePoint Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was -34.29%. Total Assets is also linked to Revenue through Asset Turnover. EyePoint Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.03.

EyePoint Pharmaceuticals Total Assets Historical Data

The historical data trend for EyePoint Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Total Assets Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

65.67

75.39

233.08

170.26

325.70

EyePoint Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															144.39	162.13	149.96	325.70	302.91

EyePoint Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

EyePoint Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	244.218	+	81.486
	=	325.70

EyePoint Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	229.939	+	72.968
	=	302.91

EyePoint Pharmaceuticals (FRA:PV3B) Total Assets Explanation

Total Assets is connected with ROA %.

EyePoint Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-107.764	/	( (325.704	+	302.907)	/ 2 )
	=	-107.764	/	314.3055
	=	-34.29 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

EyePoint Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	10.749	/	( (325.704	+	302.907)	/ 2 )
=	10.749	/	314.3055
=	0.03

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

EyePoint Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (FRA:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (FRA:PV3B) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

EYPT:USA PV3B:Germany

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (FRA:PV3B) Headlines

No Headlines